Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.

Wei ChenShuifang HuZelong LiuYukun SunJian WuShunli ShenZhen-Wei Peng

Published in: Hepatology international (2023)

Adjuvant anti-PD-1 antibody can effectively improve the survival outcomes of HCC patients with high relapse risks after hepatectomy in this prospective observational study. This finding should be confirmed by results of the ongoing phase 3 randomized controlled trials.

Keyphrases

early stage
randomized controlled trial
human health
free survival
liver metastases
risk assessment
systematic review
climate change
study protocol